MedImmune Inks Exclusive License Agreement with La Jolla Institute for Asthma Discovery

If MedImmune can develop and market a drug based on the discovery, it could be a financial boost to the institute, which hopes to diversify its revenue sources once cash from sole corporate sponsor Kirin Pharma USA dries up in 2010.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.